2.93
4.64%
+0.13
Elutia Inc stock is currently priced at $2.93, with a 24-hour trading volume of 11,821.
It has seen a +4.64% increased in the last 24 hours and a -7.28% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $2.83 pivot point. If it approaches the $2.96 resistance level, significant changes may occur.
Previous Close:
$2.80
Open:
$2.9
24h Volume:
11,821
Market Cap:
$71.35M
Revenue:
$35.35M
Net Income/Loss:
$-37.66M
P/E Ratio:
-1.3022
EPS:
-2.25
Net Cash Flow:
$-22.11M
1W Performance:
+5.40%
1M Performance:
-7.28%
6M Performance:
+113.87%
1Y Performance:
+0.00%
Elutia Inc Stock (ELUT) Company Profile
Name
Elutia Inc
Sector
Industry
Phone
240 247 1170
Address
12510 Prosperity Drive, Suite 370, Silver Spring
Elutia Inc Stock (ELUT) Latest News
Elutia to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1
GlobeNewswire Inc.
Elutia to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 7, 2024
GlobeNewswire Inc.
Elutia Regains Compliance with Nasdaq Listing Requirements
GlobeNewswire Inc.
Elutia Inc. (ELUT) Upgraded to Buy: Here's Why
Zacks Investment Research
Where Elutia Stands With Analysts
Benzinga
Elutia Reports 26% Year-Over-Year Sales Growth of Proprietary Products and Strengthened Balance Sheet in Third Quarter 2023 Financial Results
GlobeNewswire Inc.
Elutia Inc Stock (ELUT) Financials Data
Elutia Inc (ELUT) Revenue 2024
ELUT reported a revenue (TTM) of $35.35 million for the quarter ending December 31, 2023, a -3.34% decline year-over-year.
Elutia Inc (ELUT) Net Income 2024
ELUT net income (TTM) was -$37.66 million for the quarter ending December 31, 2023, a -14.47% decrease year-over-year.
Elutia Inc (ELUT) Cash Flow 2024
ELUT recorded a free cash flow (TTM) of -$22.11 million for the quarter ending December 31, 2023, a -0.61% decrease year-over-year.
Elutia Inc (ELUT) Earnings per Share 2024
ELUT earnings per share (TTM) was -$2.06 for the quarter ending December 31, 2023, a +14.17% growth year-over-year.
About Elutia Inc
Aziyo Biologics, Inc., a regenerative medicine company, focuses on the development of regenerative products to address the device protection, women's health, orthobiologics, cardiovascular, and soft tissue reconstruction markets. It offers CanGaroo that combines the envelope with antibiotics and is designed to reduce the risk of infection following surgical implantation of an electronic device. The company also provides cardiovascular products, such as ProxiCor for use as an intracardiac patch or pledget for tissue repairs; Tyke for use in neonates and infants to repair pericardial structures; and VasCure, a patch material to repair or reconstruct the peripheral vasculature, including the carotid, renal, iliac, femoral, and tibial blood vessels for cardiovascular, vascular, and general surgeons. In addition, it offers Fiber VBM, ViBone, and OsteGro V that are human tissue-derived bone allografts designed to protect and preserve native bone cells; and SimpliDerm, a pre-hydrated HADM designed to repair or replacement of damaged or inadequate integumental tissues. Further, the company provides contract manufacturing services for various products to corporate customers. It sells its products to hospitals and other healthcare facilities through its direct sales force, commercial partners, and independent sales agents. The company was incorporated in 2015 and is headquartered in Silver Spring, Maryland.
Cap:
|
Volume (24h):